Market Chatter: UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official

MT Newswires Live

2 hours ago

UniQure's (QURE) experimental treatment for Huntington's disease was labeled unsuccessful by a senior official at the US Food and Drug Administration during a media call, casting further doubt on the gene therapy's prospects, Reuters reported Thursday.

The official said a randomized trial conducted within a year yielded negative results and criticized the company's interpretation of clinical data for the therapy, AMT-130, according to the report.

The company didn't immediately respond to a request for comment from MT Newswires.

Shares of the company were up 13% in Thursday trading.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 10.27, Change: +1.23, Percent Change: +13.61

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2617573380"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2617573380\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2617573380?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 03:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617573380","market":"hk","top_or_hot":-1,"title":"Market Chatter: UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official","media":"MT Newswires Live","content":"<html><body><p> UniQure's (QURE) experimental treatment for Huntington's disease was labeled unsuccessful by a senior official at the US Food and Drug Administration during a media call, casting further doubt on the gene therapy's prospects, Reuters reported Thursday.</p><p>The official said a randomized trial conducted within a year yielded negative results and criticized the company's interpretation of clinical data for the therapy, AMT-130, according to the report.</p><p>The company didn't immediately respond to a request for comment from MT Newswires.</p><p>Shares of the company were up 13% in Thursday trading.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 10.27, Change: +1.23, Percent Change: +13.61</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Market Chatter: UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarket Chatter: UniQure's Experimental Treatment for Huntington's Disease Faces Criticism From FDA Official\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-06 03:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> UniQure's (QURE) experimental treatment for Huntington's disease was labeled unsuccessful by a senior official at the US Food and Drug Administration during a media call, casting further doubt on the gene therapy's prospects, Reuters reported Thursday.</p><p>The official said a randomized trial conducted within a year yielded negative results and criticized the company's interpretation of clinical data for the therapy, AMT-130, according to the report.</p><p>The company didn't immediately respond to a request for comment from MT Newswires.</p><p>Shares of the company were up 13% in Thursday trading.</p><p>(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)</p><p>Price: 10.27, Change: +1.23, Percent Change: +13.61</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QURE","symbol_name":"uniQure N.V.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2617573380","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617573380","pubTimestamp":1772740345,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"UniQure's  experimental treatment for Huntington's disease was labeled unsuccessful by a senior official at the US Food and Drug Administration during a media call, casting further doubt on the gene therapy's prospects, Reuters reported Thursday.The official said a randomized trial conducted within a year yielded negative results and criticized the company's interpretation of clinical data for the therapy, AMT-130, according to the report.The company didn't immediately respond to a request for comment from MT Newswires.Shares of the company were up 13% in Thursday trading.Price: 10.27, Change: +1.23, Percent Change: +13.61","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"QURE":"uniQure N.V.","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技"},"translate_title":"市场热议：UniQure实验性治疗亨廷顿舞蹈症面临FDA官员批评","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QURE":1},"content_text":"UniQure's (QURE) experimental treatment for Huntington's disease was labeled unsuccessful by a senior official at the US Food and Drug Administration during a media call, casting further doubt on the gene therapy's prospects, Reuters reported Thursday.The official said a randomized trial conducted within a year yielded negative results and criticized the company's interpretation of clinical data for the therapy, AMT-130, according to the report.The company didn't immediately respond to a request for comment from MT Newswires.Shares of the company were up 13% in Thursday trading.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: 10.27, Change: +1.23, Percent Change: +13.61","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}